Cargando…
The EEF1A2 gene expression as risk predictor in localized prostate cancer
BACKGROUND: Besides clinical stage and Gleason score, risk-stratification of prostate cancer in the pretherapeutic setting mainly relies on the serum PSA level. Yet, this is associated with many uncertainties. With regard to therapy decision-making, additional markers are needed to allow an exact ri...
Autores principales: | Worst, Thomas Stefan, Waldbillig, Frank, Abdelhadi, Abdallah, Weis, Cleo-Aron, Gottschalt, Maria, Steidler, Annette, von Hardenberg, Jost, Michel, Maurice Stephan, Erben, Philipp |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604352/ https://www.ncbi.nlm.nih.gov/pubmed/28923030 http://dx.doi.org/10.1186/s12894-017-0278-3 |
Ejemplares similares
-
Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer
por: Waldbillig, Frank, et al.
Publicado: (2020) -
RNA Expression of DNA Damage Response Genes in Muscle-Invasive Bladder Cancer: Influence on Outcome and Response to Adjuvant Cisplatin-Based Chemotherapy
por: Herrmann, Jonas, et al.
Publicado: (2021) -
Treatment decision satisfaction and regret after focal HIFU for localized prostate cancer
por: Westhoff, Niklas, et al.
Publicado: (2020) -
Subclassification, survival prediction and drug target analyses of chemotherapy-naïve muscle-invasive bladder cancer with a molecular screening
por: Rinaldetti, Sebastien, et al.
Publicado: (2018) -
ANLN and TLE2 in Muscle Invasive Bladder Cancer: A Functional and Clinical Evaluation Based on In Silico and In Vitro Data
por: Wu, Sheng, et al.
Publicado: (2019)